Introduction and Objectives
The aim of this study is to present our experience with bladder cancer in patients after succesful renal tranplantation.
Material and Methods
We reviewed 10 cases of bladder cancer in our centre between 2002 and 2008. All patients used immunosupresive therapy based on calcineurin inhibitors. The 4 women. Average age at the time of diagnosis was 62 years (34–77). Average time after renal transplantation was 51 months (26–123). All the patients had first kidney transplantation, all grafts were cadaveric. We reviwed pathologic stage, histologic nuclear grade, progression and recurrence of superficial tumours. We also reviewed therapeutic approaches.
In 8 cases (70%) we proved superficial bladder cancer (<pT1). In 2 cases (20%) we proved muscle-invazive bladder cancer (pT2). Histological nucelar grade of tumours was in 3 cases (30%) grade I, in 4 cases grade II and in 3 cases grade III. After transurethral resection of bladder tumous (TURB), we did not prove progression of the tumours, in 2 cases we proved down-stage of tumour (pT2 to pT1). We proved recurrence in 9 cases (90%). In all recurrent cases we proved recurrent diseas 3 month after primal resection. No patient of our study died of bladder cancer. We did not prove any metastatic diseas in our patients. The therapeutic approach was in all cases in first step TURB. After positive follow up cystoscopic evaluation 3 month after primal TURB, we used sigle-shot intravesical chemotharapy. We did not make any changes in immunopupresive protocol.
Bladder camcer is uncommon compliaction after kidney transplantation. In therapy of superficial bladder cancer is not necesarry to change immunosuppresive protocol nor perform extensive surgical procedures.
© 2009 European Association of Urology. Published by Elsevier Inc. All rights reserved.